期刊文献+

抗人CD28鼠-人嵌合抗体的构建及瞬时表达 被引量:2

Construction and transient expression of the mouse-human chimeric antibody against human CD28
下载PDF
导出
摘要 目的构建及瞬时表达抗人CD28鼠-人嵌合抗体。方法采用基因工程技术,从分泌鼠抗人CD28单克隆抗体的杂交瘤细胞株(克隆号:2F5)中克隆出抗体重链和轻链可变区基因及相应信号肽编码序列。分别与人免疫球蛋白IgG1恒定区重、轻链基因拼接,构建含有重组基因的pIRES表达质粒pIRES/h2F5。转染293T细胞并用抗性药物G418选择培养。采用流式细胞术,检测瞬时转染细胞后嵌合抗体的表达情况。结果抗人CD28鼠人嵌合抗体得到表达并能与CD28分子特异性结合。结论抗人CD28鼠-人嵌合抗体的构建和瞬时表达是成功的,为后续构建稳定分泌抗人CD28鼠-人嵌合抗体的CHO基因转染细胞株奠定了基础。 Purpose To construct and transiently express of a mouse-human chimeric antibody against human CD28 molecule. Methods By using genetic technology, total RNA was extracted from the murine hybridoma cell line (Clone number: 2F5) secreting anti-CD28 monoclonal antibody. The variable region and the correspond signal peptide coding sequence were cloned, then fused with the coding sequence of the constant region of the human IgG1 heavy chain and light chain respectively. The mouse-human chimeric antibody recombinant plasmid was established. 293T cell line was transfected with the recombinant plasmid and the transfectants were selected by G418 contained medium. Using FACS to detect the chimeric antibody's transient expression level. Results The chimeric antibody against human CD28 was expressed and recognized the CD28 molecular specifically. Conclusions Chimeric antibody is successfully constructed and is transiently expressed, thus a foundation is laid for establishing CHO cell line secreting chimeric anti-CD28 monoclonal antibody.
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2007年第4期482-485,共4页 Fudan University Journal of Medical Sciences
基金 江苏省自然科学基金(NO:2004203) 江苏省高校高新技术发展基金(NO:J HB05-45)
关键词 CD28 单克隆抗体 嵌合抗体 瞬时表达 CD28 monoclonal antibody chimeric antibody transient expression
  • 相关文献

参考文献3

二级参考文献15

共引文献22

同被引文献28

  • 1孙中文,陶然,陆艳红,石云杰,於葛华,邱玉华,张学光.5株鼠抗人CD28单克隆抗体的研制及生物学特性的研究[J].中国免疫学杂志,2005,21(6):406-410. 被引量:11
  • 2瞿秋霞,陈永井,葛彦,王勤,陈成,杨明峰,张学光.抗人CD40人-鼠嵌合抗体的构建及其表达[J].细胞与分子免疫学杂志,2006,22(2):189-192. 被引量:10
  • 3Graecone G. EGFR inhibitors in the treatment of lung cancer [J]. EJC Supplements, 2003, 1 (5) :S106. 被引量:1
  • 4Baselga J. EGFR therapies in other tumor types [J]. EJC Suppl, 2003,1 (5) :S107. 被引量:1
  • 5Sung FL, Poon TC, Hui EP, et al. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cell [J]. In Vivo,2005,19( 1 ) :237 -245. 被引量:1
  • 6Rose WC, Wild R. Therapeutic synergy of oral taxman BMS275183 and cetuximab versus human tumor xenografts [ J ]. Clin Cancer, 2004,10(21 ) :7413 -7414. 被引量:1
  • 7Mial L, Fan Z, Andratschke NH, et al. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies [ J]. Int J Radiat Oncol Biol Phys,2004,58 (3) :966 - 971. 被引量:1
  • 8Iwahashi M, Milenic DE, Padlan EA, et al. CDR substitutions of a humanized monoclonal antibody ( CC49 ) : contributions of individual CDRs to antigen binding and immunogenicity [ J ]. Mol Immunol, 1999,36 ( 15 - 16 ) : 1079 - 1091. 被引量:1
  • 9Kashmiri SV, Iwahashi M, Tamura M, et al. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49 [ J ]. Crit Rev Oncol Hematol, 2001,3 (8) :3 - 16. 被引量:1
  • 10Leung SO, Goldenberg DM, Dion AS. Construction and characterization of a humanized, internalizing, leukemia/lymphoma antibody, L12[J]. Mol Immunol,1995,32( 17 - 18) :1413 - 1427. 被引量:1

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部